Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 9.3 %

NASDAQ:TTNP opened at $5.55 on Wednesday. The firm’s 50-day simple moving average is $6.70 and its 200 day simple moving average is $6.81. Titan Pharmaceuticals has a 52 week low of $5.00 and a 52 week high of $13.97.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its quarterly earnings data on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share for the quarter. Titan Pharmaceuticals had a negative return on equity of 99.96% and a negative net margin of 2,014.71%.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.